Global Business Accelerator Programme in Japan

RNS Number : 8172C

N4 Pharma PLC

24 January 2018

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

Global Business Accelerator Programme: Visit to Japan

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, announces that it is among a group of innovative UK companies operating in the cell and gene therapy sector chosen to receive funding from Innovate UK, the UK's innovation agency, to attend the Global Business Accelerator Programme Cell and Gene Therapy Visit to Japan.

The Company will visit Japan from 19 to 24 February 2018 and attend the Cell and Gene Therapy Matchmaking event and Medical Japan 2018. In addition, the Company will also receive pre- and post-visit support to help follow up on meetings held during the events.

Nigel Theobald, CEO of N4 Pharma, commented: "We are delighted to have been chosen to join this visit and to have the opportunity to attend these events and present Nuvec® to relevant companies in Japan.

With the Asia-Pacific DNA vaccine market forecast to grow at a CAGR of 45.85% through to 2025*, driven by factors such as a growing population with unmet medical needs and increasing awareness regarding the advantages of vaccines, Japan represents an exciting potential future market for N4 Pharma's offerings."

*Source: INK Wood Asia-Pacific DNA Vaccines Market forecast 2017-2025

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: [phone]
Beaufort Securities Elliot Hance	Tel: [phone]
Alma PR Josh Royston Robyn Fisher	Tel: [phone] Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

About Innovate UK

Innovate UK is the UK's innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit: www.innovateuk.gov.uk

 

END

 

 

NRAEADFLAFKPEFF